Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.22.B80 extracted from

  • Mahmoudvand, S.; Shokri, S.
    Interactions between SARS coronavirus 2 papain-like protease and immune system A potential drug target for the treatment of COVID-19 (2021), Scand. J. Immunol., 94, e13044 .
    View publication on PubMedView publication on EuropePMC
Search for more literature for 3.4.22.B80

Organism

Organism UniProt Comment Textmining
Severe acute respiratory syndrome coronavirus 2 P0DTD1 SARS-CoV-2
-

Synonyms

Synonyms Comment Organism
PLpro
-
 Severe acute respiratory syndrome coronavirus 2
SARS-CoV-2 papain-like protease
-
 Severe acute respiratory syndrome coronavirus 2
SCoV-2 PLpro
-
 Severe acute respiratory syndrome coronavirus 2

General Information

General Information Comment Organism
drug target the enzyme is an important target for the treatment of COVID-19. Discussion about the dysregulation effects of PLpro on immune system and drugs that have potential inhibitors for SCoV-2 PLpro Severe acute respiratory syndrome coronavirus 2
physiological function SARS-CoV-2 papain-like protease (PLpro) is an important coronavirus enzyme that regulates viral spread and innate immune responses. SCoV-2 PLpro is multifunctional with deubiquitinating (DUB) and deISGylating activity. The enzyme is essential for viral replication and blocks the activation of type I IFN through reducing of STING dimerization, disruption of MAVS-STING-RIGI complex formation, de-ISGylation of ISG15, disregulation of TGF-beta, MAPK and NF-kappaB, deubiquitination of RIG-I, STING, IRF-3 and TBK1, and prevention of TBK1 phosphorylation through deubiquitination of TRAF3 and TRAF6 Severe acute respiratory syndrome coronavirus 2